Showing results (141-150 of 362) with videos related to
Sort By:
Pageof 37
Stroke|May 6, 2003
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic strokeWalter N Kernan, Silvio E Inzucchi, Catherine M Viscoli, et al.Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.ESC Heart Failure|December 29, 2023
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular diseaseAbhinav Sharma, Silvio E Inzucchi, Jeffrey M Testani, et al.Stroke|July 14, 2023
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome TrialsPriyadarshini Balasubramanian, Walter N Kernan, Kevin N Sheth, et al.Journal of Hospital Medicine|January 29, 2015
Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical centerNeel M Butala, Benjamin K Johnson, James D Dziura, et al.Diabetes & Vascular Disease Research|January 16, 2015
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsSilvio E Inzucchi, Bernard Zinman, Christoph Wanner, et al.Diabetes, Obesity & Metabolism|January 27, 2021
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOMESubodh Verma, C David Mazer, Silvio E Inzucchi, et al.Kidney International|May 31, 2019
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamicsGert J Mayer, Christoph Wanner, Matthew R Weir, et al.European Heart Journal|January 29, 2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialDavid Fitchett, Bernard Zinman, Christoph Wanner, et al.Circulation|September 15, 2017
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseChristoph Wanner, John M Lachin, Silvio E Inzucchi, et al.Pageof 37